UVC Becomes Mainstream in Healthcare IFUs The RDS-32a by TMG Health Technologies provides a 30-second solution for the deactivation of virulent\npathogens that is independently certified for performance and efficacy.
LAS VEGAS, June 6, 2023 (Newswire.com)
-
TMG Health Technologies, a biosafety company recognized by Healthcare Tech Outlook Magazine as a Top Ten Infection Prevention Solutions Provider 2022, was recently asked to implement testing and assist in writing the IFU (Instructions For Use) on the latest battery-powered respiratory masks and imaging products. Their model RDS-32a desktop and mobile UVC decontamination system has become the go-to solution for fast, efficient, repeatable disinfection protocol of health electronics, devices, and non-critical, multi-use patient tools.
Disinfection of respiratory and imaging components has been typically accomplished by the application of chemical germicides that have resulted in shortened product life cycles, damage to the product casings and electrical connections. [See ECRI Top 10 Technology Hazards 2019¹] Because these classes of products are shared amongst healthcare workers and are required use in the diagnosis and care of patients, they are used repeatedly and often. Simplifying the disinfection process to a 30-second, chemical-free, warranty-friendly, single UVC cycle is of great benefit to the operator in efficiency and time saved. It is also beneficial to the facility because it creates a repeatable standard of disinfection that results in both supply and life-cycle cost savings.
The RDS-32a by TMG Health Technologies provides a 30-second solution for the deactivation of virulent pathogens that is independently certified for performance and efficacy. This non-chemical disinfection method does not damage sensitive equipment and accommodates its repetitive, multi-patient use. The consistent use of UVC germicidal irradiation in short 30-second cycles has tested safe for items including plastics, rubber seals, tubes, straps, electronics, batteries, and filters. TMG Health Technologies welcomes the opportunity to test (without charge) equipment, products and packaged supplies from other manufacturers used in a healthcare facility for the evaluation of UVC as a disinfection solution and will assist in the formulation of an official IFU. Contact them HERE.
The RDS-32a is independently certified to provide more than 12 times the germicidal dosage required to deactivate the Covid virus, its variants, and other major pathogens in 30 seconds. Hospitals and healthcare providers who have utilized the RDS-32a Rapid UVC Decontamination System consider it a game-changing innovation as a disinfection tool that simplifies the disinfection protocol to the time it takes to clean hands. Learn more at TMGHealthTech.com.
[1] ECRI Institute Executive Brief, Top 10 Technology Hazards of 2019: # 9 "Cleaning fluid seeping into electrical components can lead to equipment damage and fires.
Contact Information:
Sanford Green
President and CEO [email protected]
7025217253
Denise Hood
Marketing and Communications Director [email protected]
4349647511
As published in Frontiers in Pharmacology, the biopharmaceutical drug development firm's sponsored research has identified and validated cannabinoid ratio-controlled, Minimum Essential Mixtures (MEM) for the treatment of Parkinson's disease symptoms
Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and drug development company, has co-published a study in the journal Frontiers in Pharmacologythat demonstrates the efficacy of its proprietary cannabinoid-containing, minimum essential mixtures (MEM) for the treatment of Parkinson's disease (PD). There is a great clinical need for improved therapeutics, and the market for Parkinson's disease treatments is expected to grow to $8.8 billion by 2026.
"Our drug discovery process has identified promising ratio-controlled mixtures of cannabis-inspired compounds for the treatment of Parkinson's disease, which have proven effective at reducing Parkinsonian motor symptoms in an animal model of the disease," said Dr. Andrea Small Howard, President, Chief Science Officer, and Director of Gb Sciences. "This study allows us to continue addressing unmet clinical needs through the development of novel plant-inspired drugs, and positions Gb Sciences as a contributor to the expanding world of novel PD therapeutics."
For this Gb Sciences-sponsored study, the discovery research using cell models of Parkinson's disease was performed at Chaminade University (Honolulu, Hawai'i, USA), and the MEM refinement and validation research was performed in a zebrafish model of Parkinson's disease at the National Research Council of Canada (NRC). The study entitled "Identification of minimum essential therapeutic mixtures from Cannabis plant extracts by screening in cell and animal models of Parkinson's disease" was co-authored by Gb Sciences' own President and Chief Science Officer Andrea Small-Howard and her collaborators Michael G. Morash, Jessica Nixon, and Lee Ellis from the National Research Council of Canada; Lori M.N. Shimoda and Helen Turner from Chaminade University of Honolulu; and Alexander J. Stokes from the University of Hawai'i at Manoa (Manoa, Hawai'i, USA).
The sequentially reductionist process implemented in this multi-site study preserves some of the entourage-like effects of whole plant extracts while achieving "relative" simplicity within MEM that is a requirement for obtaining the manufacturing and quality control advantages of single-ingredient drugs. This paper identifies promising minimal essential mixtures of cannabinoids based on a step-wise, strategic approach to reducing the complexity of the plant secondary metabolome. The sequential use of insilico, in vitro, and medium throughput in vivo experimental systems has generated refined, de-risked mixtures that can now be tested in additional, higher-cost, preclinical model systems of PD.
Gb Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary GbS Global Biopharma, Inc. The "plant-inspired" active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences' intellectual property portfolio contains six issued U.S. and three issued foreign patents, as well as 17 U.S. and 51 foreign patent-pending applications. In its drug development pipeline, Gb Sciences has five preclinical phase product development programs. Gb Sciences' lead program for Parkinson's disease is being prepared for a first-in-human clinical trial. Gb Sciences' formulations for chronic pain, anxiety, and depression are currently in preclinical animal studies with researchers at the National Research Council of Canada. The company also received positive preclinical proof-of-concept data supporting its complex mixtures for the treatment of Cytokine Release Syndrome, and its lead candidates will be optimized based on late-stage preclinical studies at Michigan State University. Gb Sciences' productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit www.gbsciences.com.
Forward-Looking Statements
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects," "intends," "plans," "may," "could," "should," "anticipates," "likely," "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
